Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications
- PMID: 27580689
- DOI: 10.1016/j.jacc.2016.08.010
Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications
Abstract
Background: There are limited data on the incidence, clinical implications, and predisposing factors of transcatheter heart valve (THV) thrombosis following transcatheter aortic valve replacement (TAVR).
Objectives: The authors assessed the incidence, potential predictors, and clinical implications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR.
Methods: Among 460 consecutive patients who underwent TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) THV, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1 to 3 months post-TAVR. MDCT scans were evaluated for hypoattenuated leaflet thickening that indicated THV thrombosis.
Results: MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, whereas 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ among different generations of THVs (8% vs. 6%; p = 0.42). The risk of THV thrombosis in patients who did not receive warfarin was higher compared with patients who received warfarin (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). A larger THV was associated with an increased risk of THV thrombosis (p = 0.03). In multivariable analysis, a 29-mm THV (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT.
Conclusions: Incidence of THV thrombosis in this large study was 7%. A larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications.
Keywords: aortic stenosis; multidetector computed tomography; platelet aggregation inhibitors; transcatheter aortic valve replacement; warfarin.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
The Clinical Reality With Uncertain Consequences of Biological Valve Thrombosis.J Am Coll Cardiol. 2016 Nov 8;68(19):2070-2072. doi: 10.1016/j.jacc.2016.08.042. J Am Coll Cardiol. 2016. PMID: 27810045 No abstract available.
-
Valve Thrombosis After Transcatheter Aortic Valve Replacement.J Am Coll Cardiol. 2017 Mar 28;69(12):1649-1650. doi: 10.1016/j.jacc.2016.11.084. J Am Coll Cardiol. 2017. PMID: 28335854 No abstract available.
Similar articles
-
Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography.Circ Cardiovasc Interv. 2015 Apr;8(4):e001596. doi: 10.1161/CIRCINTERVENTIONS.114.001596. Circ Cardiovasc Interv. 2015. PMID: 25873726
-
Three-dimensional multidetector computed tomography versus conventional 2-dimensional transesophageal echocardiography for annular sizing in transcatheter aortic valve replacement: Influence on postprocedural paravalvular aortic regurgitation.Catheter Cardiovasc Interv. 2013 Nov 15;82(6):977-86. doi: 10.1002/ccd.25005. Epub 2013 Jul 19. Catheter Cardiovasc Interv. 2013. PMID: 23703899
-
3-dimensional aortic annular assessment by multidetector computed tomography predicts moderate or severe paravalvular regurgitation after transcatheter aortic valve replacement: a multicenter retrospective analysis.J Am Coll Cardiol. 2012 Apr 3;59(14):1287-94. doi: 10.1016/j.jacc.2011.12.015. Epub 2012 Feb 22. J Am Coll Cardiol. 2012. PMID: 22365423
-
Subclinical leaflet thrombosis following transcatheter aortic valve replacement.J Interv Cardiol. 2018 Oct;31(5):640-647. doi: 10.1111/joic.12521. Epub 2018 May 23. J Interv Cardiol. 2018. PMID: 29790209 Review.
-
Leaflet immobility and thrombosis in transcatheter aortic valve replacement.Eur Heart J. 2020 Sep 1;41(33):3184-3197. doi: 10.1093/eurheartj/ehaa542. Eur Heart J. 2020. PMID: 32930773 Free PMC article. Review.
Cited by
-
Early thrombus formation including hypo-attenuated leaflet thrombosis after surgical bioprosthetic aortic valve replacement.Gen Thorac Cardiovasc Surg. 2024 Feb 26. doi: 10.1007/s11748-024-02010-4. Online ahead of print. Gen Thorac Cardiovasc Surg. 2024. PMID: 38403822
-
Periprocedural Thrombogenicity Change Is Associated With Subclinical Leaflet Thrombosis Progression in Patients Undergoing Transcatheter Aortic Valve Implantation.Circ Rep. 2023 Nov 30;5(12):450-458. doi: 10.1253/circrep.CR-23-0092. eCollection 2023 Dec 8. Circ Rep. 2023. PMID: 38073872 Free PMC article.
-
Early 6 months usage of single anTiplAtelet OR anTicoAgulant followed by single antiplatelet after transcatheter aortic valve replacement: protocol for a multicentre, open-label, randomised controlled clinical trial.BMJ Open. 2023 Nov 21;13(11):e076781. doi: 10.1136/bmjopen-2023-076781. BMJ Open. 2023. PMID: 37989381 Free PMC article.
-
Leaflet thrombosis in transcatheter aortic valve intervention: mechanisms, prevention, and treatment options.Front Cardiovasc Med. 2023 Oct 6;10:1249604. doi: 10.3389/fcvm.2023.1249604. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37868777 Free PMC article. Review.
-
Biomechanics of Transcatheter Aortic Valve Replacement Complications and Computational Predictive Modeling.Struct Heart. 2022 Jun 3;6(2):100032. doi: 10.1016/j.shj.2022.100032. eCollection 2022 Jun. Struct Heart. 2022. PMID: 37273734 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
